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Abstract Ciliopathies are a group of clinically and ge-
netically overlapping disorders whose etiologies lie in
defective cilia. These are antenna-like organelles on the
apical surface of numerous cell types in a variety of
tissues and organs, the kidney included. Cilia play es-
sential roles during development and tissue homeostasis,
and their dysfunction in the kidney has been associated
with renal cyst formation and renal failure. Recently, the
term “renal ciliopathies” was coined for those human
genetic disorders that are characterized by nephronoph-
thisis, cystic kidneys or renal cystic dysplasia. This
review focuses on renal ciliopathies from a human ge-
netics perspective. We survey the newest insights with
respect to gene identification and genotype–phenotype
correlations, and we reflect on candidate ciliopathies.
The opportunities and challenges of next-generation se-
quencing (NGS) for genetic renal research and clinical
DNA diagnostics are also reviewed, and we discuss the
contribution of NGS to the development of personalized
therapy for patients with renal ciliopathies.
Keywords Cilia . Renal ciliopathies . Renal cysts .
Genotype–phenotype correlations . Next-generation
sequencing . Personalized medicine
Introduction
Cilia
Cilia are membrane-enclosed hair-like cell organelles that occur
on the apical surface of renal tubular cells and on cells in many
other organs. Cilia are conserved among species and were first
described by the Dutch scientist Antoni van Leeuwenhoek, the
father of microscopy and cell biology, who reported ciliated
micro-organisms that used their cilia as “little legs” for move-
ment [1, 2]. It appears that many cell types in the human body,
such as sperm cells and the respiratory epithelial cells, also
contain motile cilia. The cilium, or flagellum, of a sperm cell
allows the cell to move, whereas cilia in the respiratory system
propel mucous over the cell surface [3]. In this review, we will
focus on the immotile brother of the motile cilium, the so-called
primary cilium, which appears and functions as a cell antenna
of renal cells and cells throughout the human body (Fig. 1) [3,
4]. Structurally, the primary cilium is composed of a basal body
from which the cilium initially assembles, a transition zone that
is important for anchoring the cilium to the membrane and
regulating protein traffic in and out of the cilium, and the ciliary
axoneme, which contains a ring of microtubule bundles con-
necting the ciliary base with the tip. The microtubules form the
skeleton of the cilium and are literally a “highway” for ciliary
transport (intraflagellar transport, or IFT), a process that was
first observed in the unicellular green alga Chlamydomonas
reinhardtii and that has recently been extensively reviewed by
Ishikawa and Marshall [5, 6]. This transport process is bidirec-
tional, base-to-tip (anterograde) and tip-to-base (retrograde),
and occurs through interactions of the kinesin-2 motor in
association with the IFTcomplex B proteins or the cytoplasmic
dynein motor 2 linked to IFT complex A proteins respectively
[5]. IFT allows movement of cargo through the cilium and is
important for ciliogenesis and for signaling cascades that reg-
ulate development and tissue homeostasis [3, 4].
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Ciliary dysfunction and renal insufficiency
One of the first papers that linked ciliary disruption to
the development of cystic kidneys in mammals was
published by the group led by Douglas Cole in 2000.
In their paper they describe ciliary abnormalities and
renal disease in a mouse model with a hypomorphic
mutation in the Ift88 gene that encodes a protein that
is part of the IFT B complex (Fig. 1) [7]. To date, we
know that ciliary disruption is linked to a variety of
human genetic kidney disorders, such as autosomal
dominant and recessive polycystic kidney disease
(ADPKD and ARPKD), tuberous sclerosis (TSC), medullary
cystic kidney disease (MCKD), and nephronophthisis and
related disorders [3, 4]. Here, we will predominantly focus
on the latter group of disorders.
Renal ciliopathies
Nephronophthisis
Nephronophthisis literally means “damage to the nephrons.”
It is an autosomal recessive disorder that represents the most
common monogenetic cause of renal insufficiency in children
and young adults. It is enormously genetically heterogeneous,
i.e., mutations in at least 13 different genes have been associ-
ated with nephronophthisis. In spite of that, 70% of patients
still remain genetically unexplained [8]. In 1997, the first
genetic cause of nephronophthisis was identified through the
detection of a deletion that covered the NPHP1 gene [8, 9].
Later, it became apparent that NPHP1 is not only mutated in
isolated nephronophthisis, but that a significant number of
patients with NPHP1 mutations also display neurological
Fig. 1 The primary cilium and ciliary protein complexes. The primary
cilium is a membrane-enclosed antenna-like structure with a ring-
shaped skeleton that consists of 9 doublets of microtubules. The ciliary
base is called the “basal body”, and consists of triplets of microtubules.
Ciliary transport, intraflagellar transport (IFT), occurs from base-to-tip
mediated by the IFT complex B (green) in association with a kinesin II
motor and from tip-to-base by the IFT complex A (purple) in associ-
ation with the cytoplasmic dynein motor 2. Other protein complexes
are the BBSome (red) consisting of various BBS proteins, and net-
works of nephrocystins (yellow), and Meckel–Gruber (MKS) and/or
Joubert (JBTS) syndrome-associated proteins (orange). The BBSome
is involved in trafficking membrane proteins to the cilium, while most
nephrocystins and MKS/JBTS proteins localize to the transition zone
where they are important for ciliogenesis, regulation of ciliary signal-
ing and the docking and filtering of vesicles/proteins at the cilium
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symptoms. Some of these individuals have been reported to
display cerebellar vermis hypoplasia and brainstem anomalies
compatible with a Joubert syndrome diagnosis [10–12]. With
respect to nephronophthisis, NPHP1 is the most commonly
mutated gene, as genetic defects in this gene explain the cause
of disease in 20% of patients with this disorder [8], while all
other nephronophthisis-associated genes (Table 1) have been
found to be mutated with a much lower frequency. Remark-
ably, almost all of these genes encode proteins that intercon-
nect in a dynamic “nephrocystin” protein complex that resides
at the transition zone (Fig. 1) where it regulates ciliogenesis
and protein sorting, thereby controlling renal development
and homeostasis [13–15]. Yet, other localizations and func-
tions of the nephrocystins are also known. Besides their ciliary
roles, nephrocystins 1, 4, and RPGRIP1L (also known as
nephrocystin-8) have been shown to regulate tight-junction
formation at the cell junctions [16]. GLIS2 and nephrocystin-2
function in both the nucleus and the cilium [17, 18], and the
recently identified XPNPEP3 biochemically processes several
ciliary proteins and has been detected in mitochondria [19].
Clinically, it is difficult to diagnose nephronophthisis in early
stages of the disease as children with this rare disorder initially
present with nonspecific features such as polydipsia and poly-
uria [8]. As such, good medical care for patients with
nephronophthisis (and other cystic kidney diseases)
includes evaluation for other medical and developmental
issues. Ultrasound, renal biopsies, and/or genetic tests are
necessary to make a definite nephronophthisis diagnosis.
Renal ultrasounds often show normal sized or small kidneys
with increased echogenicity, and may reveal renal cysts,
although cysts are not recorded in all nephronophthisis
patients. Histologically, nephronophthisis is characterized by
thickened and irregular tubular basement membranes, periglo-
merular and interstitial fibrosis, and (sporadic) cysts that often
occur at the corticomedullary border (Fig. 2a) [8].
Syndromes associated with nephronophthisis
Nephronophthisis is often accompanied by anomalies in
other organs (Table 2). This is not surprising given the fact
that primary cilia occur almost ubiquitously throughout the
human body [4]. Extrarenal features that are often observed
include retinal degeneration, hepatobiliary disease, cerebel-
lar vermis hypoplasia, laterality defects, intellectual disabil-
ity and shortening of bones (ribs, phalanges and long bones)
[3, 4]. These features are represented in a variety of
syndromes, including Senior–Løken syndrome (retinal
degeneration causing blindness), Joubert syndrome (cerebellar
vermis hypoplasia and brainstem abnormalities; the primary
hallmark is the molar tooth sign in the brain), Bardet–Biedl
syndrome (intellectual disability, obesity, and various other
features), and Jeune asphyxiating thoracic dystrophy
(shortening of the bones, the main characteristic is a narrow
rib-cage) [3, 4]. In 2009, it was suggested by Baker and Beales
and by Konstantinidou et al that Sensenbrenner syndrome,
often but not always characterized by nephronophthisis, is also
part of the ciliopathy spectrum based on the phenotypic over-
lap with the classic ciliopathies [20, 21]. A year later the first
genetic evidence was published by us and others supporting
this assumption [22, 23]. We can therefore conclude that
classification of classic and new ciliopathies allows ciliary
gene prioritization facilitating gene hunting for these disorders.
Sensenbrenner syndrome is characterized by several of the
above-mentioned features, for instance, retinal degeneration,
hepatobiliary disease, cerebellar vermis hypoplasia, and
shortening of the bones in combination with craniosynostosis
and ectodermal anomalies, such as skin laxity and tooth
abnormalities [24–26]. To date, Sensenbrenner syndrome
and the other ciliary disorders affecting skeleton development,
such as Jeune syndrome, Ellis–van Creveld syndrome,
Saldino–Mainzer syndrome, and the short-rib-polydactyly
syndrome are referred to as “skeletal ciliopathies.”
Renal cystic dysplasia and other renal phenotypes
Other renal phenotypes have also been associated with
ciliary dysfunction. In severe syndromes that affect early
human development, such as the Meckel–Gruber syn-
drome, which is characterized by neural tube defects
and many other features, and the short-rib-polydactyly
syndrome, fetuses present with cystic renal dysplasia, a
congenital renal dysplasia in which the renal cortex is
generally cystic, with distension of the terminal ends of
the collecting ducts, and the medullary pyramids are
poorly developed and demonstrate dysplastic structures
and fibrous tissue (Fig. 2b) [3, 27–29]. Other renal
phenotypes that have been described in ciliopathies are
horseshoe kidneys [29, 30], lobulated kidneys [31], urinary
tract infections and anomalies [32], and kidney stones
[33]; however, the latter abnormalities are all much less
commonly reported and it remains to be shown whether
these features are (in part) the result of cilium dysfunc-
tion or not.
Genetics of renal ciliopathies
Current genetic insights
To date, mutations in roughly 50 genes have been associated
with renal ciliopathies (Table 1). Although not all patients
with mutations in these genes suffer from renal disease, we
have to be aware of the fact that various genes were identi-
fied only recently in a few young patients in whom renal
disease may still develop, and that a subset of genes have a
low-mutation frequency. Improved insights into genotype–
Pediatr Nephrol (2013) 28:863–874 865
Table 1 Ciliary disease genes and renal phenotypes
Symbol Renal phenotype in patients MIM Gene ID Disorders Reference (PMID)
AHI1 Nephronophthisis 608894 JBTS 15322546
ALMS1 Renal insufficiency 606844 ALSTR 11941369; 11941370
ARL13B No renal disease reported 608922 JBTS 18674751
ARL6 Renal failure, kidney stones 608845 BBS, RP 15258860; 15314642;
19858128; 19956407
ATXN10 Nephronophthisis 611150 NPHP 21565611
B9D1 Multicystic dysplastic kidneys 614144 MKS 21493627
B9D2 Cystic kidneys 611951 MKS 21763481
BBS1 Chronic renal failure, urinary tract infections and
anomalies
209901 BBS 12118255
BBS10 Meckel-like cystic kidneys 610148 BBS 16582908
BBS12 Renal disease reported 610683 BBS 17160889
BBS2 Meckel-like cystic kidneys, cystic kidneys, renal
hypoplasia
606151 BBS 11285252
BBS4 Meckel-like cystic kidneys, cystic kidneys 600374 BBS, LCA 11381270
BBS5 No renal disease reported 603650 BBS 15137946
BBS7 Renal disease reported 607590 BBS 12567324
BBS9 Renal disease reported 607968 BBS 16380913




CEP41 Nephronophthisis (rare) 610523 JBTS 22246503






C5ORF42 No renal disease reported 614571 JBTS 22425360
DYNC2H1 Cystic kidneys, Multicystic dysplastic kidneys 603297 ATD, SRP 19442771
EVC No renal disease reported 604831 EVC 10700184
EVC2 No renal disease reported 607261 EVC 12468274
GLIS2 Nephronophthisis 608539 NPHP 17618285
HYLS1 No renal disease reported 610693 HYLS 15843405; 18648327
IFT122 Nephronophthisis 606045 CED 20493458
IFT43 Nephronophthisis 614068 CED 21378380
IFT80 No renal disease reported 611177 ATD, SRP 17468754; 19648123
IFT140 Nephronophthisis 614620 ATD, SM 22503633
INPP5E No renal disease reported 613037 JBTS, MORM 19668215; 19668216
INVS Enlarged (dysplastic) cystic kidneys 243305 NPHP, SLSN 12872123; 16522655
IQCB1 Nephronophthisis 609237 SLSN, LCA 15723066; 21220633
KIF7 No renal disease reported 611254 ACRC, HYLS,
JBTS
21633164; 21552264
MKKS Meckel-like cystic kidneys, lobulated kidneys 604896 BBS, MKKS 10973251; 10973238
MKS1 Renal cystic dysplasia 609883 MKS 16415886
NEK1 Cystic kidneys, horseshoe kidney (rare) 604588 SRP 21211617
NEK8 Nephronophthisis 609799 NPHP 18199800
NPHP1 Nephronophthisis 607100 NPHP, JBTS,
SLSN
9326933; 15138899; 9856524
NPHP3 Nephronophthisis, renal cystic dysplasia 608002 NPHP, MKS,
SLSN
12872122; 18371931; 11752023
NPHP4 Nephronophthisis 607215 NPHP, SLSN 12205563; 12244321
OFD1 Cystic kidneys 300170 JBTS, OFD, SGBS 11179005; 19800048; 16783569
OCRL1 Renal proximal tubulopathy (Dent’s disease) 300535 OCRL 22228094
PKD1 Enlarged cystic kidneys 601313 ADPKD 8004675
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Table 1 (continued)
Symbol Renal phenotype in patients MIM Gene ID Disorders Reference (PMID)
PKD2 Enlarged cystic kidneys 173910 ADPKD 8650545
PKHD1 Enlarged cystic kidneys 606702 ARPKD 11898128; 11919560





SDCCAG8 Nephronophthisis 613524 SLSN, BBS 20835237; 22190896
TCTN1 No renal disease reported 609863 JBTS 21725307
TCTN2 Enlarged cystic kidneys 613846 JBTS, MKS 21565611; 21462283
TMEM138 Renal cystic dysplasia, nephronophthisis 614459 JBTS 22282472
TMEM237 Cystic kidneys 614423 JBTS 22152675
TMEM216 Renal cystic dysplasia, cystic kidneys,
nephronophthisis
613277 JBTS, MKS 20036350; 20512146







TRIM32 No renal disease reported 602290 BBS 16606853
TTC21B Nephronophthisis 612014 ATD, NPHP 21258341
TSC1 Cystic kidneys, renal cancer 605284 TSC 9242607
TSC2 Cystic kidneys, renal cancer 191092 TSC 7581393
TTC8 Renal dysplasia (rare) 608132 BBS, RP 14520415; 20451172





VHL Renal cell carcinoma, cystic kidneys 608537 VHL 2894613; 15611513
WDPCP No renal disease reported 613580 BBS 20671153
WDR19 Nephronophthisis 608151 ATD, CED, NPHP 22019273
WDR35 Cystic kidneys 613602 CED, SRP 21473986; 20817137
XPNPEP3 Nephronophthisis 613553 NPHP 20179356
ADPKD autosomal dominant polycystic kidney disease, ALSTR Alström syndrome, ARPKD autosomal recessive polycystic kidney disease, ATD
asphyxiating thoracic dystrophy, BBS Bardet–Biedl syndrome, CED cranioectodermal dysplasia, COACH cerebellar vermis hypo/aplasia, oligo-
phrenia, ataxia, coloboma and hepatic fibrosis, EVC Ellis–van Creveld syndrome, FJHN familial juvenile hyperuricemic nephropathy, GCKD
glomerulocystic kidney disease with hyperuricemia and isosthenuria, HYLS hydrolethalus syndrome, JBTS Joubert syndrome, LCA Leber
congenital amaurosis, MCKD medullary cystic kidney disease, MKS Meckel–Gruber syndrome, NPHP nephronophthisis, OCRL Lowe oculo-
cerebro-renal syndrome, OFD oro-facio-digital syndrome, RP retinitis pigmentosa, SGBS Simpson–Golabi–Behmel syndrome, SLSN Senior–
Løken syndrome, SM Saldino–Mainzer syndrome, SRP short rib polydactyly, TSC tuberous sclerosis, VHLVon Hippel–Lindau disease
Fig. 2 Nephronophthisis and renal cystic dysplasia. a Pathohistology
of nephronophthisis. A cross section through a renal biopsy from a
Sensenbrenner patient shows interstitial fibrosis and tubular membrane
disruptions (thickened, irregular basement membranes). Image
courtesy of Eric Steenbergen. b Cystic dysplastic kidneys with marked
interstitial fibrosis and cysts of different sizes form in a fetus with
Meckel–Gruber syndrome. Image courtesy of Carsten Bergmann
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phenotype relations are thus warranted for better diagnosis
and prognosis, and screening for early signs of renal disease
is important in most individuals.
From SNP microarray analysis to next-generation
sequencing
Although gene defects are still identified through linkage
analysis with single nucleotide polymorphism (SNP) micro-
arrays followed by candidate sequencing, e.g., KIF7 associat-
ed with acrocallosal, hydrolethalus, and Joubert syndrome
[34, 35], CEP41 associated with Joubert syndrome [36], and
NEK1 associated with short rib polydactyly [29], next-
generation sequencing (NGS) techniques are dramatically
speeding up gene identification in the ciliopathy field and in
the genetics field in general (Fig. 3) [37]. These NGS tech-
nologies allow cost-effective and time-efficient gene identifi-
cation by sequencing large parts or even the full complement
of (protein-coding) DNA of a single individual at once. Gene
identification can now take a matter of weeks rather than years
[38]. Targeted parallel-sequencing of linkage intervals or
small groups of genes led to the identification of mutations
in the renal ciliopathy genes B9D1 associated with Meckel–
Gruber syndrome [39] and TMEM237 associated with Joubert
syndrome [40], while larger-scale ciliopathy candidate exome
(ciliome) sequencing led to the detection of mutations in
SDCCAG8 [41] and IFT140 [42]. Whole-exome sequencing,
whereby all protein-coding DNA (all exons of the genome,
1% of the genome) is sequenced, has also been applied and
resulted in the detection of mutations inWDR35 [22], WDR19
[43], and C5ORF42 [44] as causes of Sensenbrenner and
Joubert syndromes respectively. In addition, insights into ge-
notype–phenotype correlations are quickly evolving through
parallel-sequencing of a series of known renal ciliopathy
genes in large patient cohorts (consisting of roughly 100–
500 individuals) [45–47]. This is of great value as this knowl-
edge improves diagnosis, prognosis, and genetic counseling
for patients and their relatives.
Dissection of protein complexes facilitates gene
identification
Other methods that contribute to gene identification, albeit
indirectly, are state-of-the-art proteomic tools, such as tan-
dem affinity purification and yeast two-hybrid assays, that
allow dissection of protein networks [14]. Interaction studies
taught us that ciliopathy-associated proteins interconnect in a
relational ciliopathy protein complex, a dynamic molecular
machine that allows ciliary growth and function [13, 15]. In
Table 2 Phenotype overlap in renal ciliopathies
BBS MKS JBTS NPHP SLSN OFD1 CED ATD SRP ALSM PKD
Cystic kidneys ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎
Hepatobiliary disease ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎
Retinal degeneration ∎ ∎ ∎ ∎ ∎ ∎ ∎ ∎
Laterality defects ∎ ∎ ∎ ∎ ∎ ∎
Intellectual disability ∎ ∎ ∎ ∎ ∎
Cerebellar vermis hypoplasia ∎ ∎ ∎ ∎ ∎
Encephalocele ∎ ∎
Polydactyly ∎ ∎ ∎ ∎ ∎ ∎ ∎
Obesity ∎ ∎
Shortening/bowing of bones ∎ ∎ ∎ ∎
Ectodermal dysplasia ∎ ∎ ∎
ATD asphyxiating thoracic dystrophy (Jeune syndrome), ALSM Alström syndrome, BBS Bardet–Biedl syndrome, CED cranioectodermal dysplasia
(Sensenbrenner syndrome), JBTS, Joubert syndrome, MKSMeckel–Gruber syndrome, NPHP nephronophthisis, OFD1 oro-facio-digital syndrome
1, PKD polycystic kidney disease, SLSN Senior–Løken syndrome, SRP short rib polydactyly syndrome
Fig. 3 Gene identification for renal ciliopathies in the period from
1995 to 2011. Open circles indicate the number of genetic causes that
were identified in the corresponding year. X-axis: time in years; y-axis:
number of genetic causes
868 Pediatr Nephrol (2013) 28:863–874
addition, there is ample evidence to conclude that proteins in
the ciliopathy network form sub-clusters, which are often
associated with distinctive clinical characteristics when
mutated. This is illustrated by the following examples.
Many of the “nephrocystins” encoded by the nephronophthisis
genes physically link together in a “nephrocystin” protein
complex (Fig. 1) [14, 48–51]. Similarly, Jackson showed that
this is also the case for proteins that are mutated in Bardet–
Biedl syndrome by demonstrating that BBS4 associates with a
variety of other BBS proteins (i.e., BBS1, 2, 5, and 7–9), a
module that is referred to as the BBSome (Fig. 1) [52]. BBS6,
10, and 12 were later shown to form a smaller protein complex
necessary for the assembly of the BBSome [53]. Consistently,
skeletal ciliopathies such as Jeune syndrome, Sensenbrenner
syndrome, and short rib polydactyly have almost explicitly
been correlated with defects in proteins that form IFT protein
complexes (Fig. 1). In 2007, mutations in IFT80 were
found to be associated with Jeune syndrome [54], a
gene encoding a protein that is part of the multi-
subunit IFT-B complex; however, almost all other muta-
tions associated with human skeletal ciliopathies occur
in genes encoding proteins that are part of the IFT-A
complex involved in retrograde transport, i.e., IFT122
[23], WDR35/IFT121 [22, 28], TTC21B/IFT139 [55],
WDR19/IFT144 [43], IFT140 [42], IFT43 [56],
and DYNC2H1 [57], a subunit of the cytoplasmic
dynein motor 2. Taken together, these different
(interconnected) protein modules of nephrocystins, BBS
proteins, and IFTs are associated with somewhat specif-
ic, but overlapping phenotypes [13, 15]. The fact that
ciliary proteins form an interaction network insinuates that
systematic interaction assays for nephronophthisis-associated
proteins may reveal novel candidate disease genes. Excitingly,
high-throughput tandem affinity purifications for “nephrocys-
tins” and “Meckel–Gruber-associated proteins” have recently
been executed in ciliated cells, and have indeed proven to
facilitate gene identification when combined with clinical
SNPmicroarray data from families with ciliopathies; mutations
in ATXN10 and TCTN2were recently identified as the cause of
nephronophthisis and Joubert syndrome through this combina-
tion of methods [14].
Regulatory mechanisms
Although it is still challenging to understand how genes
are regulated and which noncoding intergenic regions
regulate (ciliary) gene expression, this field is evolving
as we speak. The Gleeson group recently published an
impressive article in Science on gene regulation in
Joubert syndrome [58]. As mutations in TMEM216
explained only half of their families with linkage in the JBTS2
locus, they hypothesized that there must be another disease
gene in this region. Excitingly, re-sequencing identified
mutations in TMEM138, which neighbors TMEM216
head-to-tail (Fig. 4). Both genes appear to be co-regulated
by the ciliary transcription factor regulatory factor X 4
(RFX4), a member of the RFX family that consists of at
least seven proteins in humans [59], which binds at a
noncoding-conserved intergenic region that lies between
TMEM138 and TMEM216 (Fig. 4) [58]. It is currently
unknown how often nonhomologous, adjacent genes asso-
ciated with indistinguishable phenotypes share regulatory
motifs. As suggested by Gleeson, it will be interesting to
determine how transcriptional regulation occurs of the
neighboring genes EVC and EVC2, which are mutated in
the ciliopathy Ellis–van Creveld syndrome [60]. Generally,
co-expression studies will lead toward new insights into the
molecular basis of the genetic disorders and may facilitate




Mutations in single ciliary genes are often associated
with multiple phenotypes. It is generally believed that the
nature of the mutations strongly influences the severity of the
resulting phenotype, i.e., truncating mutations are associated
with more severe phenotypes than missense mutations. How-
ever, although this trend is often observed, there are no
clear-cut genotype–phenotype correlations, and the fact
that clinical differences are often observed between
members of single families indicates that the pheno-
types also result from modifier effects [3, 4]. It is
particularly striking that roughly 40% of the Joubert
syndrome-associated genes, i.e., CC2D2A, CEP290,
NPHP3 , RPGRIP1L , TCTN2 , TMEM216 , and
TMEM67, are also mutated in the closely related, but
more severe, Meckel–Gruber syndrome [4]. Similarly,
Sensenbrenner and Jeune syndromes appear to be milder
presentations of the embryonically lethal short rib polydactyly
syndrome as IFT80, WDR35 and DYNC2H1 are mutated in
both milder and more severe phenotypes [22, 28, 54, 57, 61].
Yet, “mild” phenotypes seem to go beyond Sensenbrenner and
Jeune syndromes, given the fact that mutations in the IFT
genes TTC21B and WDR19 are also associated with isolated
nephronophthisis [43, 55]. Future research will show how
broad the associated phenotypic spectrum is for the IFT pro-
teins. With respect to the remaining renal ciliopathy genes
allelism, which refers to differing phenotypes from different
defects in the same gene, is broader than outlined above, and
occurs for 30% of the genes listed in Table 1, which further
emphasizes the clinical heterogeneity associated with this
group of genes.
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Mutational load
Apart from mutation type, “genetic load,” “modifier
effects,” and “oligo-genetic inheritance,” which all refer to
the possibility that mutations in more than one gene affect
the phenotype, have also been proposed as an explanation
for the clinical variability within ciliopathies and within
families suffering from these disorders. Mutations in multi-
ple genes have been reported in most renal ciliopathies,
initially in Bardet–Biedl syndrome [62, 63] and later
throughout the ciliopathy spectrum [55, 64, 65]. In this
respect, there is also exciting news on the dosage theory
from the PKD field. Although mutations in PKD1 and
PKD2 are associated with dominant disease, it was recently
reported that two hypomorphic PKD1 alleles may result in
ARPKD-like disease in utero [66]. As the parents of these
fetuses had a negative PKD family history, this tells us that it
is important to be aware of the possibility that multiple
mutations in ADPKD-associated genes can explain renal
cystic disease in families with apparently ARPKD. Several
other papers describing severe manifestations of PKD also
demonstrated that multiple mutations may be present in
PKD genes and other genes such as TSC2/HNF1β
[67–69]. The “mutational load” theory is thus not only
applicable to recessive renal ciliopathies, but also to domi-
nant renal cystic disorders.
New ciliopathies
New ciliopathies can be uncovered in different ways. Baker
and Beales accurately predicted that various syndromes
such as Jeune asphyxiating thoracic dystrophy, Sensenbren-
ner syndrome (also known as cranioectodermal dysplasia),
and Saldino–Mainzer syndrome belong to the ciliopathy
spectrum [20]. Their analysis was based on screening for
(multiple) classic ciliopathy features in the Online Mende-
lian Inheritance in Man (OMIM) clinical database. Besides
comparing human phenotypes, we can also extract predic-
tive markers for human disease from studies with mouse
mutants; there are for instance clues from a conditional
murine Kif3a mutant that frontonasal dysplasia could be the
result of ciliary dysfunction [70–72]. Finally, identification of
novel ciliary functions for proteins associated with human
disease may reveal that the molecular cause of disease may
be (in part) due to ciliary disruption, thereby opening avenues
for development of targeted therapies. A recent example is a
publication from Coon et al. on Lowe syndrome [73]. This
syndrome is a cerebrorenal developmental disorder that is
characterized by Dent’s disease in the kidney, a renal proximal
tubulopathy. The association of defective cilia with this
syndrome and the fact that Dent’s disease has not previously
been associated with ciliary dysfunction raises the question
whether there are more patients with this renal phenotype with
mutations in different genes that encode proteins involved in
the biology of renal cilia.
Next-generation sequencing and clinical perspectives
Currently, NGS is mostly used for research purposes to
identify novel disease genes and to gain more insights into
genotype–phenotype correlations in a time- and cost-
effective effort. The power of NGS has proven itself in
research laboratories, and in the coming years this technology
will be implemented in DNA diagnostic laboratories through-
out the world. Whereas disease genes are currently stepwise
Sanger sequenced in diagnostics based on an educated
guess at the best candidate gene, whereby clinical pheno-
type, mutation frequency, and ethnic origin are considered,
unbiased mutation screening through NGS is expected to
be much more effective [3]. Although NGS will improve
diagnosis, prognosis, and genetic counseling for patients in
daily clinical practice, there are also challenges for the
implementation of this technology in DNA diagnostics
[74]. Data interpretation must be focused on finding muta-
tions in known genes, thus requiring the development of
new software for data analysis. Excellent bioinformaticians
and infrastructures are a necessity for NGS data management
and analysis. The latter is a bottleneck in research, and will be
an even more prominent problem in DNA diagnostics, as the
accuracy of mutation detection is more important in the clinic,
Fig. 4 Gene regulation of two adjacent nonhomologous disease genes.
The neighboring TMEM138 and TMEM216, mutated in Joubert syn-
drome, are regulated by transcription factor RFX4, which binds to a
noncoding conserved regulatory intergenic region (black oval). Open
arrows indicate that both genes are located on the sense strand of
chromosome 11
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raising questions on how to handle poor sequence coverage
for selected genomic regions in a diagnostic setting. Aside
from the technical challenges, the ethical implications of NGS
are enormous [75, 76]. For instance, NGS may identify muta-
tions in genes unrelated to the studied disease, which has
major implications for patients and their relatives. Concerning
renal ciliopathies, should we sequence exomes or a selected
set of known ciliopathy genes to avoid the latter? What to do
with variants of unknown significance? What should be the
content of a consent form, especially with respect to unantic-
ipated mutations? Whose consent should be asked, given that
NGS findings could also have a major impact on the lives of
family members? These are just a few of the long list of ethical
issues that remain to be resolved.
Roads to therapy
Once end-stage renal disease develops, patients with renal
ciliopathies currently depend on invasive therapies such as
hemodialysis or renal replacement strategies, which have a
major impact on the quality of life for patients and their
relatives. The development of targeted therapies is thus
warranted. In this respect significant progress has been
made in the (AD)PKD field. Several clinical trials are un-
derway, some are finished, and potential drug targets are
continuously being identified in rodent models [77–84].
Because the PKD- and nephronophthisis-associated genes
are involved in similar ciliary pathways, PKD treatment
may eventually also appear to be valuable for nephronoph-
thisis patients. Targeted therapy development for nephro-
nophthisis has fallen behind in comparison to that for PKD,
likely because of the lower prevalence and enormous genet-
ic heterogeneity associated with this disorder. Fortunately,
the NGS-accelerated identification of genetic defects in
nephronophthisis opens a window of opportunity for the
development of (personalized) therapies, as insights into
disease mechanisms are increased and targeted drug screens
become possible. Notably, cost- and time-effective small
molecule screening in zebrafish is expected to contribute
to drug discovery [85, 86] and various mouse models are
already being tested for selected compounds [87]. Further-
more, the development of the induced pluripotent stem
cell (iPSC) technology allows drug screening in a patient’s
own cells and may hold promise for future tissue regeneration
therapy [88, 89]. Although many studies are focused on
the treatment and prevention of PKD, the first stones in
the path toward targeted therapy development for nephro-
nophthisis are only just beginning to be laid. Yet, with the
recent development of NGS we now have the chance to
remedy this situation by rapidly exposing potential treatment
targets, and by using this information for personalized
medicine.
Conclusions
We are well on our way to identifying the genetic mecha-
nisms underlying the renal ciliopathies. NGS methods are
accelerating this process enormously, and massive parallel-
sequencing genetic tests will soon be available for routine
diagnostic screening. The availability of such tests will
improve diagnostics, prognosis, and genetic counseling tre-
mendously; however, challenges in bioinformatic analysis
and variant interpretation remain, as well as the requirement
of strict ethical regulations. Besides genetic progress, mo-
lecular studies in ciliated (patient) cell lines and model
organisms expanded our insights of the disease mechanisms
of nephronophthisis and associated disorders. The next chal-
lenge is to use this genetic and molecular knowledge toward
the development of targeted (personalized) therapies to de-
lay and preferably prevent the progressive degenerative
effects of nephronophthisis in patients.
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